Contact us

877-469-1TRM
424-208-8866

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Relapsed Epithelial Ovarian
Relapsed Primary Peritoneal
Relapsed Fallopian Tube
TL32711 (Birinapant) Ib Closed to Accrual